Print ISSN: 2393-9079
Online ISSN: 2393-9087
CODEN : IJPPTK
Indian Journal of Pharmacy and Pharmacology (IJPP) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award programs. With more...Review Article
Author Details :
Volume : 2, Issue : 4, Year : 2015
Article Page : 226-229
Abstract
Background: Gabapentin is an antiepileptic and analgesic drug. There is an urge for reliable scientific evidence to support its ongoing widespread use for treatment of a number of other conditions as well.
Objective: Critical appraisal of the available literature on pharmacological basis of approved and off-label uses of gabapentin to assess the scope for its new roles in therapeutics.
Data Source: A systematic review of literature was made to study history, pharmacology, approved uses and off-label uses of gabapentin.
Conclusion: Gabapentin use has extended into the management of a variety of disorders besides epilepsy, neuropathic pain and restless leg syndrome. A large number of clinical trials are conducted to establish its role in a wide spectrum of clinical situations. While tremendous scientific speculations are surrounding the drug; there is a need to know more about this novel drug including its mechanism of action and adverse effect profile.
Key words: Gabapentin, off-label, anticonvulsant
How to cite : Semira, Gabapentin as a Novel Drug. Indian J Pharm Pharmacol 2015;2(4):226-229
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.